Topic: drug sales

Humira's best days may be past, but AbbVie could one day see $20 billion in combined sales for follow-ups Rinvoq and Skyrizi, CEO Rick Gonzalez said.

Alexion is facing a competitor to its blockbuster Soliris amid a switching campaign to a follow-up drug. But analysts so far aren't concerned.

Weeks after netting a label expansion with blockbuster potential, fish-oil derivative Vascepa is lifting Amarin to Street-beating sales.

Already facing U.S. copycats to its oncology trio, Roche can take solace in a middling sales impact so far. Could a new challenger change that?

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Teva is riding high after a strong launch for Austedo. But is "tenfold" patient growth in one of its indications possible? Analysts aren't so sure.

With two oncology blockbuster already facing U.S. biosims, Roche is facing a tough road ahead. Now, a third Roche cancer med is in the firing line.

Hey, AbbVie: Botox may be a long-term winner, but not every drug in Allergan's stable is shining quite so brightly. 

AbbVie is riding high on the launch of RA blockbuster-to-be Rinvoq and a looming merger with Allergan. Could competition for Imbruvica be a buzzkill?